Immunological aspects of nonimmediate reactions to β-lactam antibiotics

Expert Review of Clinical Immunology

Volumn 6, Issue 5, 2010, Pages 789-800

  Rodilla, Esther Morena ^a   González, Ignacio Dávila ^b   Yges, Elena Laffond ^a   Bellido, Francisco Javier Múñoz ^b   Bara, María Teresa Gracia ^a   Toledano, Félix Lorente ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

lactam antibiotics; acute generalized exanthematous pustulosis; aminopenicillins; cephalosporins; contact dermatitis; DRESS; fixed drug eruption; maculopapular exanthema; nonimmediate reactions; penicillins; Stevens Johnson syndrome; T cell; toxic epidermal necrolysis

Indexed keywords

AMINOPENICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLOXACILLIN; IMMUNOGLOBULIN E; PENICILLIN G; PENICILLIN V;

CLINICAL ASSESSMENT; CYTOPENIA; DISEASE SEVERITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOGENICITY; IMMUNOPATHOLOGY; MACULOPAPULAR RASH; PATHOPHYSIOLOGY; PROVOCATION TEST; PUSTULOSIS; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BETA-LACTAMS; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; HUMANS; HYPERSENSITIVITY, DELAYED; LEUKOPENIA; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES;

EID: 77956507903     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.53     Document Type: Review

References (129)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
2. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr. Opin. Allergy Clin. Immunol. 1(4), 305-310 (2001).
3. Coombs PR, Gell PG. Classifcation of allergic reactions responsible for clinical hypersensitivity and disease. In: Clinical Aspects of Immunology. Gell RR (Ed.). Oxford University Press, Oxford, UK, 575-596 (1968).
4. Levine BB. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases of man. N. Engl. J. Med. 275(20), 1115-1125 (1966).
5. Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to p-lactam antibiotics. Allergy 59(11), 1153-1160 (2004).
6. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl J. Med. 331(19), 1272-1285 (1994).
7. Mizukawa Y, Shiohara T Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr. Allergy Asthma Rep. 9(1), 71-77 (2009).
8. Gielen K, Goossens A. Occupational allergic contact dermatitis from drugs in healthcare workers. Contact Dermatitis 45(5), 273-279 (2001).
9. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J. Pediatr. 125(5 Pt 1), 805-811 (1994).
10. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256(24), 3358-3363 (1986).
11. Romano A, Viola M, Mondino C et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int. Arch. Allergy Immunol. 129(2), 169-174 (2002).
12. Gebhardt M, Lustig A, Bocker T, Wollina U Acute generalized exanthematous pustulosis (AGEP): manifestation of drug allergy to propicillin. Contact Dermatitis 33(3), 204-205 (1995).
13. Terrados S, Blanca M, Garcia J et al. Nonimmediate reactions to plactams: prevalence and role of the different penicillins. Allergy 50(7), 563-567 (1995).
14. Lopez S, Blanca-Lopez N, Cornejo-Garcia JA et al. Nonimmediate reactions to [Mactams. Curr. Opin. Allergy Clin. Immunol. 7(4), 310-316 (2007).
15. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 357(9271), 1851-1853 (2001).
16. Weltzien HU, Padovan E. Molecular features of penicillin allergy. J. Invest. Dermatol. 110(3), 203-206 (1998).
17. + T-cell clones from the peripheral blood of patients with cutaneous reactions to p-lactam antibiotics. Br. J. Dermatol. 128(6), 619-626 (1993).
18. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur. J. Immunol. 27(6), 1303-1307 (1997).
19. Mauri-Hellweg D, Zanni M, Frei E et al. Cross-reactivity of T cell lines and clones to p-lactam antibiotics. J. Immunol. 157(3), 1071-1079 (1996).
20. Depta JP, Pichler WJ. Cross-reactivity with drugs at the T cell level. Curr. Opin. Allergy Clin. Immunol. 3(4), 261-267 (2003).
21. Fernandez M, Warbrick EV, Blanca M, Coleman JW Activation and hapten inhibition of mast cells sensitized with monoclonal IgE anti-penicillin antibodies: evidence for two-site recognition of the penicillin derived determinant. Eur. J. Immunol. 25(9), 2486-2491 (1995).
22. Padial A, Antunez C, Blanca-Lopez N et al. Non-immediate reactions to p-lactams: diagnostic value of skin testing and drug provocation test. Clin. Exp. Allergy 38(5), 822-828 (2008).
23. Trcka J, Seitz CS, Brocker EB, Gross GE, Trautmann A. Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. J. Antimicrob. Chemother. 60(1), 107-111 (2007).
24. Pichler WJ. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139(8), 683-693 (2003).
25. +T lymphocytes in bullous cutaneous reactions caused by p-lactam antibiotics. J. Invest. Dermatol. 101(6), 794-799 (1993).
26. Rozieres A, Hennino A, Rodet K et al Detection and quantifcation of drug-specifc T cells in penicillin allergy. Allergy 64(4), 534-542 (2009).
27. Patriarca G, DAmbrosio C, Schiavino D et al. Clinical usefulness of patch and challenge tests in the diagnosis of cell-mediated allergy to p-lactams. Ann. Allergy Asthma Immunol. 83(3), 257-266 (1999).
28. Romano A, Di Fonso M, Papa G et al Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy 50(2), 113-118 (1995).
29. Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J. Invest. Dermatol. 105(1 Suppl.), 95S-98S (1995).
30. Yawalkar N, Egli F, Hari Y et al. Infltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin. Exp. Allergy 30(6), 847-855 (2000).
31. Blanca M, Posadas S, Torres MJ et al Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 55(11), 998-1004 (2000).
32. Yawalkar N, Pichler WJ. Pathogenesis of drug-induced exanthema. Int. Arch. Allergy Immunol. 124(1-3), 336-338 (2001).
33. Torres MJ, Mayorga C, Fernandez TD et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int. J. Immunopathol. Pharmacol. 19(1), 119-130 (2006).
34. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M. Gene expression levels of cytokine profle and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol. Dis. 29(2), 179-189 (2002).
35. Rodriguez-Pena R, Lopez S, Mayorga C et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to p-lactams. J. Allergy Clin. Immunol. 118(4), 949-956 (2006).
36. Posadas SJ, Leyva L, Torres MJ et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J. Allergy Clin. Immunol. 106(4), 769-776 (2000).
37. Posadas SJ, Padial A, Torres MJ et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity J. Allergy Clin. Immunol. 109(1), 155-161 (2002).
38. Cornejo-Garcia JA, Fernandez TD, Torres MJ et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy 62(12), 1429-1438 (2007).
39. Fernandez TD, Mayorga C, Torres MJ et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 63(6), 712-719 (2008).
40. Brugnolo F, Annunziato F, Sampognaro S et al. Highly Th2-skewed cytokine profle of p-lactam-specifc T cells from nonatopic subjects with adverse drug reactions. J. Immunol. 163(2), 1053-1059 (1999).
41. Tapia B, Padial A, Sanchez-S abate E et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J. Allergy Clin. Immunol. 114(2), 335-340 (2004).
42. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 16(1), 1-8 (1997).
43. Haverkos HW, Amsel Z, Drotman DP. Adverse virus-drug interactions. Rev. Infect. Dis. 13(4), 697-704 (1991).
44. Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy 31(9), 1398-1408 (2001).
45. Barbaud AM, Bene MC, Schmutz JL et al. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch. Dermatol. 133(4), 481-486 (1997).
46. Renn CN, Straff W, Dorfmuller A et al. Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specifc lymphocyte reactivity. Br. J. Dermatol. 147(6), 1166-1170 (2002).
47. Beylot C, Bioulac P, Doutre MS. [Acute generalized exanthematic pustuloses (four cases) (author's transl)]. Ann. Dermatol. Venereol. 107(1-2), 37-48 (1980).
48. Betto P, Germi L, Bonoldi E, Bertazzoni M. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin-clavulanic acid. Int. J. Dermatol. 47(3), 295-296 (2008).
49. Matsumoto Y, Okubo Y, Yamamoto T, Ito T, Tsuboi R. Case of acute generalized exanthematous pustulosis caused by ampicillin/cloxacillin sodium in a pregnant woman. J. Dermatol. 35(6), 362-364 (2008).
50. Roujeau JC, Bioulac-Sage P, Bourseau C et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch. Dermatol. 127(9), 1333-1338 (1991).
51. Riten K, Shahina Q, Jeannette J, Palma-Diaz MF. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr. Dermatol. 26(5), 623-625 (2009).
52. Belda Junior W, Ferolla AC. Acute generalized exanthematous pustulosis (AGEP). Case report. Rev. Inst. Med. Trop. Sao Paulo 47(3), 171-176 (2005).
53. Chaabane A, Aouam K, Gassab L, Njim L, Boughattas NA. Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam. Clin. Pharmacol. 24(4), 429-432 (2010).
54. Grieco T, Cantisani C, Innocenzi D, Bottoni U, Calvieri S. Acute generalized exanthematous pustulosis caused by piperacillin/tazobactam. J. Am. Acad. Dermatol. 52(4), 732-733 (2005).
55. Sulewski RJ Jr, Blyumin M, Kerdel FA. Acute generalized exanthematous pustulosis due to clindamycin. Dermatol. Online J. 14(7), 14 (2008).
56. Corral de la Calle M, Martin Diaz MA, Flores CR, Vidaurrazaga C. Acute localized exanthematous pustulosis secondary to levofoxacin. Br. J. Dermatol. 152(5), 1076-1077 (2005).
57. Sidoroff A, Dunant A, Viboud C et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br. J. Dermatol. 157(5), 989-996 (2007).
58. Girardi M, Duncan KO, Tigelaar RE et al. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am. J. Dermatopathol. 27(4), 343-346 (2005).
59. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. 107(11), 1433-1441 (2001).
60. Schmid S, Kuechler PC, Britschgi M et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am. J. Pathol. 161(6), 2079-2086 (2002).
61. Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E et al. Amoxicillin-induced fare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur. J. Dermatol. 20(1), 68-73 (2010).
62. Akcam FZ, Aygun FO, Akkaya VB. DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J. Infect. 53(2), e51-e53 (2006).
63. Gaig P, Garcia-Ortega P, Baltasar M, Bartra J. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J. Investig. Allergol. Clin. Immunol. 16(5), 321-326 (2006).
64. Garnier A, El Marabet EH, Kwon T et al. Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following hepatitis A. Pediatr. Nephrol. 23(4), 667-669 (2008).
65. Hernanto M, Yudani BA, Pudjiati SR, Indrastuti N. DRESS syndrome from cefadroxil confrmed by positive patch test. Allergy 62(10), 1216-1217 (2007).
66. Naisbitt DJ, Britschgi M, Wong G et al. Hypersensitivity reactions to carbamazepine: characterization of the specifcity, phenotype, and cytokine profle of drug-specifc T cell clones. Mol. Pharmacol. 63(3), 732-741 (2003).
67. + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155(1), 462-472 (1995).
68. Shiohara TR, Kano Y. Drug-induced hypersensitivity syndrome and viral reactivation. In: Drug Hypersensitivity. Pichler WJ (Ed.). Karger, Basel, Switzerland, 251-266 (2007).
69. Descamps V, Valance A, Edlinger C et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch. Dermatol. 137(3), 301-304 (2001).
70. Hashimoto K, Yasukawa M, Tohyama M. Human herpesvirus 6 and drug allergy. Curr. Opin. Allergy Clin. Immunol. 3(4), 255-260 (2003).
71. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
72. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
73. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004).
74. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43(1), 99-102 (2006).
75. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
76. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333(24), 1600-1607 (1995).
77. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35-44 (2008).
78. Gupta HL, Dheman R. Ampicillin induced Stevens-Johnson syndrome. J. Indian Med. Assoc. 72(8), 188-189 (1979).
79. McArthur JE, Dyment PG. Stevens-Johnson syndrome with hepatitis following therapy with ampicillin and cephalexin. NZ Med. J. 81(538), 390-392 (1975).
80. Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ Jr, Agrawal RM. Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens-Johnson syndrome. Ann. Pharmacother. 33(5), 560-564 (1999).
81. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An ampicillin-associated case. Gastroenterology 99(3), 854-856 (1990).
82. Romano A, Di Fonso M, Pocobelli D et al. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to b-lactam antibiotics. J. Investig. Allergol. Clin. Immunol. 3(1), 53-55 (1993).
83. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specifc cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004).
84. Leyva L, Torres MJ, Posadas S et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J. Allergy Clin. Immunol. 105(1 Pt 1), 157-165 (2000).
85. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282(5388), 490-493 (1998).
86. Caproni M, Torchia D, Schincaglia E et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br. J. Dermatol. 154(2), 319-324 (2006).
87. Abe R, Shimizu T, Shibaki A et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162(5), 1515-1520 (2003).
88. Nassif A, Moslehi H, Le Gouvello S et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol. 123(5), 850-855 (2004).
89. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J. Allergy Clin. Immunol. 122(5), 992-1000 (2008).
90. Caproni M, Torchia D, Schincaglia E et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br. J. Dermatol. 155(4), 722-728 (2006).
91. Bellon T, Alvarez L, Mayorga C et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br. J. Dermatol. 162(5), 1014-1022 (2010).
92. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14(12), 1343-1350 (2008).
93. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann. Intern. Med. 151(7), 514-515 (2009).
94. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
95. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
96. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
97. Alfrevic A, Jorgensen AL, Williamson PR et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity Pharmacogenomics 7(6), 813-818 (2006).
98. Mizukawa Y, Yamazaki Y, Teraki Y et al. Direct evidence for interferon-y production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fxed drug eruption. Am. J. Pathol. 161(4), 1337-1347 (2002).
99. Shiohara T, Mizukawa Y, Teraki Y Pathophysiology of fxed drug eruption: the role of skin-resident T cells. Curr. Opin. Allergy Clin. Immunol. 2(4), 317-323 (2002).
100. Choi HJ, Ku JK, Kim MY et al. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fxed drug eruption. Br. J. Dermatol. 154(3), 419-425 (2006).
101. Gamboa P, Jauregui I, Urrutia I. Occupational sensitization to aminopenicillins with oral tolerance to penicillin V. Contact Dermatitis 32(1), 48-49 (1995).
102. Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin. Hematol. 42(3), 137-144 (2005).
103. Bell MJ, Stockwell DC, Luban NL et al. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr. Crit. Care Med. 6(3), 363-366 (2005).
104. Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 26(9), 1390-1394 (2000).
105. Viraraghavan R, Chakravarty AG, Soreth J. Cefotetan-induced haemolytic anaemia. A review of 85 cases. Adverse Drug React. Toxicol. Rev. 21(1-2), 101-107 (2002).
106. Arndt PA. Practical aspects of investigating drug-induced immune hemolytic anemia due to cefotetan or ceftriaxone-a case study approach. Immunohematology 18(2), 27-32 (2002).
107. Moes GS, MacPherson BR. Cefotetan-induced hemolytic anemia: a case report and review of the literature. Arch. Pathol. Lab. Med. 124(9), 1344-1346 (2000).
108. Petz LD, Fundenberg HH. Immunologic mechanisms in drug-induced cytopenias. Prog. Hematol. 9, 185-206 (1975).
109. Salama A. Drug-induced immune hemolytic anemia. Expert Opin. Drug Saf. 8(1), 73-79 (2009).
110. Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 44(7), 1033-1040 (2004).
111. Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann. Allergy Asthma Immunol. 86(3), 330-334 (2001).
112. Shimanovich I, Rose C, Sitaru C, Brocker EB, Zillikens D. Localized linear IgA disease induced by ampicillin/sulbactam. J. Am. Acad. Dermatol. 51(1), 95-98 (2004).
113. Osawa J NS, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J. Dermatol. 17, 235-239 (1990).
114. Romano A, Quaratino D, Di Fonso M et al. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J. Allergy Clin. Immunol. 103(6), 1186-1190 (1999).
115. Torres MJ, Sanchez-Sabate E, Alvarez J et al. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy 59(2), 219-224 (2004).
116. Moreno E RA, Dávila I, Laffond E et al. Maculopapular exanthema associated with b-lactam antibiotic. Allergy 63(Suppl. 88), 382 (2008).
117. Tchen T, Reguiai Z, Vitry F et al. Usefulness of skin testing in cutaneous drug eruptions in routine practice. Contact Dermatitis 61(3), 138-144 (2009).
118. Santiago F, Goncalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 62(1), 47-53 (2010).
119. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45(6), 321-328 (2001).
120. Fischer T, Maibach HI. Antigen preparation for the patch test. Occup. Med. 1(2), 343-348 (1986).
121. Blanca-López N, Zapatero L, Alonso E et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 64(2), 229-233 (2009).
122. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to p lactams. Allergy 64(2), 183-193 (2009).
123. Luque I, Leyva L, Jose Torres M et al. In vitro T-cell responses to p-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 56(7), 611-618 (2001).
124. Cederbrant K, Marcusson-Stahl M, Hultman P. Characterization of primary recall in vitro lymphocyte responses to bacampicillin in allergic subjects. Clin. Exp. Allergy 30(10), 1450-1459 (2000).
125. Lee CE, Zembower TR, Fotis MA et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch. Intern. Med. 160(18), 2819-2822 (2000).
126. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity Br. J. Dermatol. 152(5), 968-974 (2005).
127. Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: fndings in 784 patients during a 25-year-period. Acta Derm. Venereol. 85(6), 491-496 (2005).
128. Waton J, Trechot P, Loss-Ayav C, Schmutz JL, Barbaud A. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br. J. Dermatol. 160(4), 786-794 (2009).
129. Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 58(9), 854-863 (2003).